DMAPT is a water-soluble analogue of Parthenolide (PTL). It is an orally active NF-κB inhibitor with an LD50 of 1.7 μM on primary acute myeloid leukemia cells.
| Pack Size | Availability | Price/USD | Quantity |
|---|---|---|---|
| 1 mg | In stock | $ 149 | |
| 2 mg | In stock | $ 283 | |
| 4 mg | In stock | $ 428 | |
| 10 mg | In stock | $ 672 | |
| 20 mg | In stock | $ 1021 |
| Description | DMAPT is a water-soluble analogue of Parthenolide (PTL). It is an orally active NF-κB inhibitor with an LD50 of 1.7 μM on primary acute myeloid leukemia cells. |
| Targets&IC50 | NF-κB:1.7 μM(LD50) |
| In vitro | DMAPT treatment reduced the constitutive NF-κB binding activity and inhibited the proliferation and viability of PC-3 and DU145 cells. Treatment of PC-3 and DU145 cells with 5 and 4 μM DMAPT, respectively, increased the population doubling time of PC-3 prostate cancer cells from 23.0±5.0 h to 42.0±3.0 h, while the population doubling time of DU145 cells increased from 20.4±2.2 h By 72.5±24.8 hours. |
| In vivo | DMAPT (100 mg/kg, oral gavage daily for 7 days) treatment can increase the sensitivity of PC-3 tumor xenografts to X-rays. DMAPT (100 mg/kg, 42 to 300 days from birth, oral gavage three times a week) treatment can slow the normal tumor development of TRAMP mice and prolong the reachable prostate tumor time by 20%. DMAPT further reduced the lung tissue transfer area of TRAMP mice to below the water vehicle treatment group (0.10%±0.15 SD, 92% reduction, p = 0.0028). |
| Synonyms | Dimethylamino Parthenolide |
| CAS No. | 870677-05-7 |
| Chemical Formula | C17H27NO3 |
| Molecular Weight | 293.407 |
| Solubility | DMSO: 100 mg/mL (340.83 mM), Need ultrasonic |
| Storage | Powder: -20°C for 2 years In solvent: -80°C for 1 year |
In vivo Formulation Calculator (Clear solution)Calculatorbottom
